Targeting mitochondria using proper pharmacological agents is considered an attractive strategy for
cancer control and management. Herein, we report a newly synthetic
triazole analog of
Jaridonin, DN3, which exhibits more potent antitumor activity via acting directly on mitochondria. DN3 potently reduced viabilities of
gastric cancer cell lines HGC-27 and MGC-803 through inducing apoptosis and cell cycle arrest. But, normal human gastric epithelial cell line GES-1 is more resistant to the growth inhibition by DN3 compared with
gastric cancer cells. DN3 induced mitochondrial membrane potential (
MMP) decrease and
cytochrome c release in intact
gastric cancer cell lines. Meanwhile, the DN3 treatment also caused the release of
cytochrome c from mitochondria isolated from
cancer cell lines in a
mitochondrial permeability transition pore complex (
PTPC) mediated manner, but not from mitochondria isolated from normal gastric epithelial cell. The induction of mitochondrial
PTPC proteins voltage-dependent anion channel (VDAC) and
cyclophilin D (CypD) were also observed in DN3-treated cells. More interestingly, DN3 mediated
MMP decrease, release of
cytochrome c, the expression of VDAC and CypD and apoptosis were blocked by the pretreatment of VDAC1 inhibitor (4, 4'-diisothiocyanatostilbene-2,2'-disulfonic acid, DIDS) and CypD inhibitor (
cyclosporine A, CsA). In a mouse xenograft model of human
gastric cancer, the treatment of 5 mg/kg DN3 led to significant
tumor regression without affecting
body weight. In conclusion, our findings indicate that DN3 is a potential agent for the treatment of
gastric cancer through acting directly on mitochondria, and would be useful for us to design more and better anti-
cancer compounds.